The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis

Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis

June 16, 2020 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In addition, Dr. Reveille discussed the 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Dr. Reveille noted that the recommendations for treatment of ankylosing spondylitis and nr-axSpA are quite similar in this update.

You Might Also Like
  • Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • From Chronic Low Back Pain to Axial Spondyloarthritis
Explore This Issue
July 2020
Also By This Author
  • Insights into Interstitial Lung Disease in Rheumatoid Arthritis Patients

Tumor necrosis factor inhibitor (TNFi) therapy is recommended over secukinumab or ixekizumab as the first biologic to be used, but either of the latter two medications is recommended over the use of a second TNFi in patients with primary nonresponse to the first TNFi. Co-administration of low-dose methotrexate with TNFi is not recommended, and sulfasalazine is recommended only for persistent peripheral arthritis when TNFi therapy is contraindicated.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

With regard to patients with unclear disease activity, MRI of the spine or pelvis can be used to aid in assessment, but routine monitoring of radiographic changes with serial spine radiographs is not recommended in the 2019 guideline.8

Disease Progression
On this note, discussion of the best way to monitor disease activity in axial spondyloarthritis has been ongoing. In an editorial reflecting on the 2019 guideline, Michelena and Marzo-Ortega explain there are limitations in using MRI for disease monitoring in light of the limited knowledge on correlation between MRI lesions and treatment response and the uncertainty regarding the clinical significance of subclinical inflammatory changes on MRI. The authors also write that no therapies have yet been proved to be disease modifiers in axial spondyloarthritis and that data are limited regarding the potential effects from NSAIDs, TNFi’s and interleukin-17 inhibitors on slowing structural damage.9

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Clinicians and patients alike also wonder what percentage of patients with nr-axSpA are likely to progress to radiographic axial spondyloarthritis over time. In a recent review on this subject, the authors note that most studies report 10–40% of patients with nr-axSpA progress to radiographic axial spondyloarthritis over a period of 2–10 years.6

Dr. Reveille noted in his lecture that male sex and elevated CRP are among the best predictors of radiographic progression. For this reason, Dr. Reveille advocates for repeat imaging of the sacroiliac joints when following patients over time, and this may include MRI studies when they can be covered by the patient’s insurance.

Studies in Radiology journals have noted that MRI can show new bone formation in the sacroiliac joints and peri-discal new bone formation in the spine.7 The proper use of such imaging for screening and monitoring disease may prove useful in the clinical care of patients.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: ACR State-of-the-Art Clinical Symposium, AS Resource Center, criteria, non-radiographic axial spondyloarthritisIssue: July 2020

You Might Also Like:
  • Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • From Chronic Low Back Pain to Axial Spondyloarthritis
  • Phase 3 Results for Ixekizumab Promising in Patients with Non-Radiographic Axial Spondyloarthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)